
|Videos|October 14, 2022
Efficacy and Quality of Life Data from 5-Year Follow-Up of CheckMate 214
Author(s)Rana R. McKay, MD
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5



















